Conclusion :
Gastric mucormycosis is a rare entity that affects usually predisposed patients such as immunocompromised, alcoholic and diabetic patients but sometimes immunocompetent ones. Its treatment is based on amphotericin B and surgical debridment of all necrotic tissues. The mortality rates remain high up to 85%. However, an early diagnosis and prompt therapy can improve prognosis.